Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
PCRX - Pacira BioSciences, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$31.67
DETAILS
HIGH:
$36.50
LOW:
$25.00
MEDIAN:
$32.00
CONSENSUS:
$31.67
DOWNSIDE:
12.99%
Stock News
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)PR NewswireNEW YORK, Oct. 11, 2026NEW YORK, Oc
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Pacira BioSciences, Inc. (NASDAQ: PCRX ) related to its sale to Viatris Inc. Under the terms of the proposed transaction, Pacira shareholders are expected to receive $36.50 in cash per share.
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSciences" or the "Company") (NASDAQ: PCRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Viatris Inc. (NASDAQ: VTRS) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The investigation concerns whether the Pacira BioSciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.PR NewswireMILWAUKEE, Oct. 8, 2026PCRX shareholders will rec
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction. Are You a PCRX Shareholder?
2 Stocks Drawing Bearish Options Activity Today
Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira BioSciences Inc (NASDAQ:PCRX) and Ring Energy Inc (NYSEAMERICAN:REI).
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash.Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Pacira and its board of directors violated the.
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities Expected to Be Synergistic With Viatris' Fast-Acting Meloxicam Opportunity Deal Anticipated to Close By the End of 2026 and to Be Immediately Accretive to Viatris' Financial Guidance Metrics Transaction Consistent With Viatris' Disciplined and Balanced Capital Allocation Strategy and Preserves Financial Flexibility PITTSBURGH and BRISBANE, Calif. , Oct. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, and Caregiver Action Network (CAN), the nation's leading family caregiver organization, today announced findings from Ready, Set, Recover, an initiative examining family caregivers' experiences with surgery preparation, postsurgical pain management, and recovery at home.
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets.
240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE
Bank of America Corp DE bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 240,006 shares of the company's stock, valued at approximately $6,089,000. Bank of America
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Price Targets
Pacira downgraded to Neutral from Buy at H.C. Wainwright
$36.50
(was $36.39)
H.C. Wainwright
Pacira downgraded to Hold from Buy at Truist
$36.50
(was $36.39)
Truist Financial
Pacira price target raised to $31 from $30 at Truist
$31.00
(was $25.41)
Truist Financial
Pacira initiated with an Outperform at Oppenheimer
$32.00
(was $24.70)
Oppenheimer
Pacira initiated with a Market Perform at Leerink
$28.00
(was $25.87)
Leerink Partners
Pacira reinstated with a Buy at Truist
$30.00
(was $23.00)
Truist Financial
Pacira price target raised to $25 from $24 at RBC Capital
$25.00
(was $27.62)
Douglas Miehm
·
RBC Capital
Pacira price target raised to $32 from $30 at Needham
$32.00
(was $25.49)
Needham
Pacira initiated with an Equal Weight at Barclays
$27.00
(was $24.42)
Barclays
Pacira price target raised to $24 from $17 at Barclays
$24.00
(was $24.05)
Barclays
Pacira price target raised to $48 from $39 at H.C. Wainwright
$48.00
(was $24.05)
H.C. Wainwright
Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy
$25.00
(was $26.03)
Les Sulewski
·
Truist Financial
Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler
$12.00
(was $17.36)
David Amsellem
·
Piper Sandler
Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies
$18.00
(was $14.77)
Glen Santangelo
·
Jefferies
Pacira downgraded to Sell from Buy at Truist
$8.00
(was $12.29)
Les Sulewski
·
Truist Financial
Pacira should be bought on today's selloff, says H.C. Wainwright
$57.00
(was $21.91)
Oren Livnat
·
H.C. Wainwright
Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
$36.00
(was $28.50)
Glen Santangelo
·
Jefferies
Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX)
$42.00
(was $30.68)
David Amsellem
·
Piper Sandler
BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $52
$52.00
(was $38.50)
BMO Capital
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $63
$63.00
(was $38.50)
Needham